SCHEMBL3476260

SCHEMBL3476260

CC(C)(C)C1CC(c2cc(C(F)(F)F)ccc2O)CCN1C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.36
RBP4 P02753 1/20 0.34
CHRNB2 P17787 2/20 0.34
CHRNA4 P43681 2/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA3 P32297 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
TRPV1 Q8NER1 1/20 0.34
P2RY14 Q15391 1/20 0.34
IDO1 P14902 1/20 0.33
NOTUM Q6P988 3/20 0.33
MRGPRX4 Q96LA9 1/20 0.33
CNR2 P34972 1/20 0.33
TMEM97 Q5BJF2 1/20 0.33
EGLN1 Q9GZT9 1/20 0.32
SLC6A9 P48067 1/20 0.32
TACR1 P25103 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23705962 0.92 SIGMAR1 (0.42) SIGMAR1PTGDR2RBP4CHRNB2CHRNA4
SCHEMBL3477447 0.84 MAOA (0.35) PTGDR2RBP4MEN1KMT2A
SCHEMBL23705836 0.84 HTR2A (0.47) SIGMAR1PTGDR2MEN1KMT2ACNR2
SCHEMBL1094396 0.80 RBP4 (0.47) PTGDR2RBP4MEN1KMT2ATRPV1
SCHEMBL23721773 0.79 PTGDR2 (0.38) SIGMAR1PTGDR2KMT2AMRGPRX4CNR2
SCHEMBL17223025 0.74 RBP4 (0.41) RBP4
SCHEMBL23705781 0.73 SLC6A9 (0.38) SLC6A9
SCHEMBL38658417 0.73 FFAR2 (0.33) SIGMAR1MEN1KMT2AMRGPRX4TMEM97
SCHEMBL4451812 0.72 FFAR4 (0.41) TACR1
SCHEMBL29136131 0.72 RIPK1 (0.49) SIGMAR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 SIGMAR1 524/4885PTGDR2 619/4885RBP4 3684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.